Ceolin, Valeria
Brivio, Erica
van Tinteren, Harm
Rheingold, Susan R.
Leahy, Allison
Vormoor, Britta
O’Brien, Maureen M. http://orcid.org/0000-0002-9054-4321
Rubinstein, Jeremy D.
Kalwak, Krzysztof
De Moerloose, Barbara http://orcid.org/0000-0002-2449-539X
Jacoby, Elad http://orcid.org/0000-0003-1411-8942
Bader, Peter http://orcid.org/0000-0003-4554-0265
López-Duarte, Mónica http://orcid.org/0000-0001-8134-9682
Goemans, Bianca F. http://orcid.org/0000-0003-4030-3228
Locatelli, Franco http://orcid.org/0000-0002-7976-3654
Hoogerbrugge, Peter
Calkoen, Friso G. http://orcid.org/0000-0001-9059-0929
Zwaan, Christian Michel http://orcid.org/0000-0001-6892-8268
Article History
Received: 9 July 2022
Revised: 14 October 2022
Accepted: 18 October 2022
First Online: 30 October 2022
Competing interests
: SRR: honoraria and research funding Pfizer and Jazz. MMO: honoraria and research funding Pfizer and Jazz. BDM: advisory board Novartis, travel funding Jazz. EJ: honoraria and membership on an entity’s Board of Directors or advisory committees Novartis. FL: honoraria for speakers’ bureau or participation in advisory boards from Amgen, Bellicum Pharmaceutical, Celgene, Jazz Pharmaceutical, Miltenyi, Sanofi and Novartis. PH: honoraria for lectures, consultancy and/or scientific advisory boards from Novartis and BMS. CMZ: consultancy Sanofi, Novartis, Roche, Incyte, travel funding and research funding Jazz, research funding BMS, AbbVie, Kura oncology, Takeda, Pfizer. Other authors have no COI to declare.